1. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1277,
2001,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
2. |
Tailoring antineoplastic therapy - pharmacogenomics opening the door |
|
Inpharma Weekly,
Volume &NA;,
Issue 1277,
2001,
Page 3-4
Richard Black,
Preview
|
|
摘要:
Pharmacogenomics is starting to deliver on the promise of individualising cancer therapy, giving doctors the ability to choose the best drug and the best dose for each patient based on which variants they possess of important genes. Irinotecan, fluorouracil, raltitrexed and methotrexate are among the drugs which may soon be able to be tailored to specific groups of patients. Speakers at a conference on Pharmacogenomics, SNPs*and Gene Patenting [San Diego, US; February 2001] have been updating delegates on progress in this area.
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
3. |
Cutaneous wart management guidelines |
|
Inpharma Weekly,
Volume &NA;,
Issue 1277,
2001,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
4. |
Donepezil linked to cost savings in patients with Alzheimer's |
|
Inpharma Weekly,
Volume &NA;,
Issue 1277,
2001,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
5. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1277,
2001,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
6. |
Fusion inhibitors securing a future in HIV infection |
|
Inpharma Weekly,
Volume &NA;,
Issue 1277,
2001,
Page 7-8
Carmen Innes,
Preview
|
|
摘要:
Trimeris and Hoffmann-La Roche recently reported new data on the fusion inhibitors pentafuside [T-20] and T-1249 in patients with HIV infection. Results suggest that combination therapy with pentafuside plus oral antiretrovirals reduces viral load to below limits of detection in more patients than oral antiretrovirals alone. Encouraging data were also presented from the first study of this novel agent in children, demonstrating that it quickly suppresses levels of HIV RNA. Meanwhile, the first clinical data on T-1249 show that it is active, well tolerated and has pharmacokinetic characteristics that support once-daily dosing. The studies were reported at the 8th Annual Conference on Retroviruses and Opportunistic Infections [Chicago, US; February 2001].
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1277,
2001,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
8. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1277,
2001,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
9. |
CMF beneficial in HER2-positive and -negative tumours |
|
Inpharma Weekly,
Volume &NA;,
Issue 1277,
2001,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
10. |
Managing hypertension in patients with diabetes mellitus |
|
Inpharma Weekly,
Volume &NA;,
Issue 1277,
2001,
Page 11-12
Charles Bankhead,
Preview
|
|
摘要:
The majority of patients with diabetes mellitus develop hypertension at some point in the course of their disease, according to findings from the United Kingdom Prospective Diabetes Study (UKPDS).*The same study showed that aggressive treatment of hypertension significantly reduces the risk for micro- and macrovascular complications. Moreover, the UKPDS demonstrated that the majority of patients with diabetes and hypertension will require multiple antihypertensive medications to achieve adequate control of BP. At Prevention VI: Diabetes and Cardiovascular Disease [Orlando, US; January 2001], a panel of cardiovascular and diabetes experts convened by the American Heart Association incorporated many of the principles from the UKPDS into recommendations for management of hypertension in patients with diabetes. The panel recommended that ACE inhibitors be included in the treatment regimen of patients with hypertension and concomitant diabetes, and also supported this therapy for the treatment of microalbuminuria and prevention of heart failure in such patients. β-Blockers received support for the treatment of patients with diabetes who also have systolic dysfunction. The panel endorsed a BP goal of 130/85mm Hg for all patients with diabetes.
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|